LOKMAN HEKIM HEALTH SCIENCES

DOI: 10.14744/lhhs.2025.69908
Lokman Hekim Health Sci 2025;5(1):1–2

lokmanhekimhs.com

EDITORIAL COMMENT

Infections in Liver Transplant Patients and the Influence of Infectious Diseases Specialists on the Entire Process

Karaciğer Nakli Hastalarında Enfeksiyonlar ve Enfeksiyon Hastalıkları Uzmanlarının Süreçteki Etkisi

Burak Işık[1], Veysel Ersan[2]

[1]**İnönü University Liver Transplantation Institute, Malatya, Türkiye**
[2]**Department of Organ Transplantation, İstanbul Aydın University VM Medical Park Florya Hospital, İstanbul, Türkiye**

Liver transplantation is a life-saving procedure for patients with end-stage liver disease, yet post-transplant infections remain a significant challenge. The review article by Bayındır et al.[1] provides a detailed and well-structured discussion on this topic, effectively highlighting the critical role of Infectious Diseases (ID) specialists throughout the transplant process. This editorial further emphasizes the relevance of their analysis, reinforcing the importance of infection control, antimicrobial stewardship, and ongoing post-transplant care.

Persistent Challenges in Infection Management

Post-transplant infections tend to follow a predictable but complex timeline, transitioning from early nosocomial bacterial infections to later-stage opportunistic viral and fungal infections. The article effectively underscores the importance of structured infection control strategies. However, real-world challenges, such as the increasing prevalence of multidrug-resistant organisms (MDROs), continue to complicate the processes that pertain to infection management. The rising occurrence of carbapenem-resistant *Enterobacteriaceae*, vancomycin-resistant *Enterococci*, and extended-spectrum beta-lactamase-producing bacteria necessitates frequent reassessment of empirical antibiotic approaches.[2]

The review also highlights the essential role of ID specialists in managing infection-related complications.[1] Ensuring their full integration into the transplant team—starting from pre-transplant evaluation through long-term post-transplant follow-up—is crucial. Beyond basic infection screening, a more comprehensive approach that includes donor-derived infection risk assessment is necessary to optimize outcomes.[3]

The Expanding Role of Infectious Diseases Specialists

Bayındır et al.[1] provide a strong case for the indispensable role of ID specialists in liver transplantation. Their contributions extend far beyond infection treatment and are central to various aspects of patient care, including:

- Antimicrobial Stewardship: Excessive antibiotic use can contribute to the rise of MDROs. ID specialists play a vital role in tailoring antimicrobial regimens to real-time epidemiological data, ensuring targeted prophylaxis without unnecessary broad-spectrum exposure.[4]

Cite this article as: *Işık B, Ersan V. Infections in Liver Transplant Patients and the Influence of Infectious Diseases Specialists on the Entire Process. Lokman Hekim Health Sci 2025;5(1):1–2.*

Correspondence: Burak Işık, M.D. İnönü Üniversitesi Karaciğer Nakli Enstitüsü, Malatya, Türkiye
E-mail: isik_burak@yahoo.com **Submitted:** 13.03.2025 **Revised:** 18.03.2025 **Accepted:** 04.04.2025

- Viral Reactivation Surveillance: *Cytomegalovirus* (CMV), *Epstein-Barr* virus (EBV), and hepatitis B/C remain persistent concerns. A patient-specific approach that relies on viral load monitoring, rather than a uniform prophylaxis strategy, may yield better clinical outcomes.[5]
- Fungal Infection Prevention: Invasive fungal infections, particularly those caused by *Aspergillus* and non-albicans *Candida species*, pose serious risks. Rapid diagnostic tools, such as beta-D-glucan and galactomannan assays, should be utilized to allow early detection and timely intervention.[6]
- Collaborative, Multidisciplinary Care: The complex nature of infections in liver transplant recipients necessitates close coordination among ID specialists, hepatologists, transplant surgeons, and intensive care teams to be able to facilitate early recognition and intervention.[7]

Looking Ahead: Areas for Further Improvement

Although the article by Bayındır et al.[1] comprehensively addresses the key aspects of infection management, evolving clinical challenges necessitate the refinement of strategies in a sustainable fashion. Several areas warrant further exploration in this regard:

- Personalized Infection Risk Assessment: The use of machine learning algorithms and predictive analytics could refine individualized infection risk profiling, allowing for more precise and targeted preventive strategies.[8]
- Advancements in Diagnostic Technologies: Emerging tools such as next-generation sequencing and rapid polymerase chain reaction (PCR) assays hold the potential to significantly enhance early infection detection in transplant patients.[9]
- Optimized Immunosuppressive Strategies: Balancing immunosuppression to minimize rejection while reducing infection risk remains an ongoing challenge. Identifying biomarkers that predict infection susceptibility could help tailor immunosuppressive regimens more effectively.[10]

Conclusion

The review by Bayındır et al.[1] provides a valuable and insightful discussion on infections in liver transplant patients, reinforcing the indispensable role of ID specialists in comprehensive post-transplant care. As the field of transplantation continues to advance, infection management must also evolve accordingly. Strengthening interdisciplinary collaboration, investing in innovative diagnostic tools, and refining patient-specific prophylactic strategies will be key to improving long-term outcomes.

By fostering research in these areas and maintaining a dynamic, evidence-based approach, the impact of infections on liver transplant recipients can be mitigated, ultimately leading to improved patient survival and quality of life.

Conflict of Interest: None declared.

Use of AI for Writing Assistance: Not declared.

Financial Disclosure: The authors declared that this study received no financial support.

Peer-review: Double blind peer-reviewed.

References

1. Bayındır Y, Almaghrabi R S, Moral K. Infections in liver transplant patients and the influence of infectious disease specialists on the entire process. Lokman Hekim Health Sciences 2025;5:67-73.
2. Van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al; Swiss Transplant Cohort Study. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis 2020;71:e159-69.
3. Sun HY, Cacciarelli TV, Singh N. Identifying a targeted population at high risk for infections after liver transplantation in the MELD era. Clin Transplant 2011;25(3):420-5. [CrossRef]
4. Martin-Mateos R, Martínez-Arenas L, Carvalho-Gomes Á, Aceituno L, Cadahía V, Salcedo M, et al. Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors. J Hepatol 2024;80(6):904-12. [CrossRef]
5. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13512. [CrossRef]
6. Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13544. [CrossRef]
7. Marty FM, Hirsch HH, Rubin RH. Transplant infectious disease as a subspecialty: Does outlining how we train define who we are? Transplant Infect Dis 2010;12:187-9. [CrossRef]
8. Ferguson Toll J, Solà E, Perez MA, Piano S, Cheng A, Subramanian AK, et al. Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda. Hepatol Commun 2024;8(10):e0539. [CrossRef]
9. Campbell KA, Trivedi HD, Chopra S. Infections in cirrhosis: A guide for the clinician. Am J Med 2021;134(6):727-34. [CrossRef]
10. Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33(9):e13514. [CrossRef]